neuroendocrine tumors

By Targets:	Drug Metabolite (1) Endogenous Metabolite (5) Isotope-Labeled Compounds (2) PD-1/PD-L1 (1) Radionuclide-Drug Conjugates (RDCs) (1) Somatostatin Receptor (5)
By Research Areas:	Cancer (14) Endocrinology (2) Metabolic Disease (1) Neurological Disease (8)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P5128

DOTA-JR11 Satoreotide tetraxetan	Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research .

HY-P9978

Toripalimab	PD-1/PD-L1	Cancer
Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .

HY-W008253

5-Hydroxyindole-3-acetic acid	Endogenous Metabolite	Neurological Disease Cancer
5-Hydroxyindole-3-acetic acid is the main metabolite of serotonin or metanephrines, which can be used as a biomarker of neuroendocrine tumors.

HY-16147

Combretastatin A1 phosphate Oxi4503; CA1P; Combretastatin A1 diphosphate	Others	Cancer
Combretastatin A1 phosphate (Oxi4503; CA1P; Combretastatin A1 diphosphate) is a potent vascular disruptive agent. Combretastatin A1 phosphate exerts anti-angiogenic effects on tumors. Combretastatin A1 phosphate has the potential for the research of pancreatic neuroendocrine tumors .

HY-W008253S1

5-Hydroxyindole-3-acetic acid-d6	Endogenous Metabolite	Neurological Disease Cancer
5-Hydroxyindole-3-acetic acid-d₆ is the deuterium labeled 5-Hydroxyindole-3-acetic acid. 5-Hydroxyindole-3-acetic acid is the main metabolite of serotonin or metanephrines, which can be used as a biomarker of neuroendocrine tumors.

HY-W008253S

5-Hydroxyindole-3-acetic acid-d2	Endogenous Metabolite	Neurological Disease Cancer
5-Hydroxyindole-3-acetic acid-d₂ is the deuterium labeled 5-Hydroxyindole-3-acetic acid. 5-Hydroxyindole-3-acetic acid is the main metabolite of serotonin or metanephrines, which can be used as a biomarker of neuroendocrine tumors.

HY-109155

Paltusotine 1 Publications Verification CRN00808	Somatostatin Receptor	Endocrinology Cancer
Paltusotine (CRN00808) is an orally active, nonpeptide selective somatostatin type 2 (SST2) receptor agonist. Paltusotine has the potential for maintaining GH and IGF-1 levels after depot somatostatin receptor ligand therapy.Paltusotine can be used in research on acromegaly and neuroendocrine tumors .

HY-W008253R

5-Hydroxyindole-3-acetic acid (Standard)	Endogenous Metabolite	Neurological Disease Cancer
5-Hydroxyindole-3-acetic acid (Standard) is the analytical standard of 5-Hydroxyindole-3-acetic acid. This product is intended for research and analytical applications. 5-Hydroxyindole-3-acetic acid is the main metabolite of serotonin or metanephrines, which can be used as a biomarker of neuroendocrine tumors.

HY-P10137

Satoreotide JR11	Somatostatin Receptor	Cancer
Satoreotide (JR11) is a SSTR2 antagonist. Satoreotide is usually conjugated with radiolabeled chelators used in neuroendocrine tumor imaing .

HY-W008253S3

5-Hydroxyindole-3-acetic acid-13C6	Isotope-Labeled Compounds Endogenous Metabolite	Neurological Disease Cancer
5-Hydroxyindole-3-acetic acid- ¹³C₆ is the ¹³C-labeled 5-Hydroxyindole-3-acetic acid. 5-Hydroxyindole-3-acetic acid is the main metabolite of serotonin or metanephrines, which can be used as a biomarker of neuroendocrine tumors.

HY-109155A

Paltusotine hydrochloride CRN00808 hydrochloride	Somatostatin Receptor	Neurological Disease Endocrinology
Paltusotine (CRN00808) hydrochloride is an orally active, nonpeptide selective somatostatin type 2 (SST2) receptor agonist. Paltusotine hydrochloride has the potential for maintaining GH and IGF-1 levels after depot somatostatin receptor ligand therapy.Paltusotine hydrochloride can be used in research on acromegaly and neuroendocrine tumors .

HY-W008253S2

5-Hydroxyindole-3-acetic acid-d5	Isotope-Labeled Compounds	Others
5-Hydroxyindole-3-acetic acid-d₅is the deuterium labeled5-Hydroxyindole-3-acetic acid(HY-W008253) . 5-Hydroxyindole-3-acetic acid is the main metabolite of serotonin or metanephrines, which can be used as a biomarker of neuroendocrine tumors .

HY-19471

(rac)-ZK-304709	Others	Cancer
(rac)-ZK-304709 is an isomer of ZK-304709. It is a first-in-class oral multi-target tumor growth inhibitor that inhibits multiple cell cycle-dependent kinases (Cdks), vascular endothelial growth factor receptor kinases (VEGF-RTKs), and platelet-derived growth factor receptor kinase β (PDGF-RTKβ). (rac)-ZK-304709 can dose-dependently inhibit the proliferation and colony formation of neuroendocrine tumor (NET) cells. It directly acts on NET cells by inducing G2 cell cycle arrest and apoptosis, while reducing the expression of MCL1, survivin, and HIF1α. In an orthotopic BON tumor model, (rac)-ZK-304709 reduced primary tumor growth by 80% and reduced tumor microvascular density. These results suggest that (rac)-ZK-304709 can effectively control tumor growth by inducing apoptosis and inhibiting tumor-induced angiogenesis, and may be a potential agent for the treatment of NET.

HY-P2434

AP102	Somatostatin Receptor	Neurological Disease Metabolic Disease Cancer
AP102 is a dual SSTR2/SSTR5-specific somatostatin analog (SSA). AP102 is a disulfide-bridged octapeptide SSA containing synthetic iodinated amino acids. AP102 binds with subnanomolar affinity to SSTR2 and SSTR5 (IC₅₀: 0.63 and 0.65 nM, respectively). AP102 does not bind to SSTR1 or SSTR3. AP102 can be used for acromegaly and neuroendocrine tumors research .

HY-117253

PHA-782584	Drug Metabolite	Cancer
PHA-782584 is a metabolite of sunitinib. Sunitinib is an oral multitargeted tyrosine kinase inhibitor with antitumor activities .

Cat. No.	Product Name	Target	Research Area

HY-P5128

DOTA-JR11 Satoreotide tetraxetan	Somatostatin Receptor Radionuclide-Drug Conjugates (RDCs)	Cancer
DOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist. DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research .

HY-P3826

Chromogranin A (324-337), human	Peptides	Neurological Disease
Chromogranin A (324-337), human is a peptide fragment of chromogranin A, it can be isolated from human ileal carcinoid tumor. Chromogranin A is a soluble glycoprotein stored with hormones and neuropeptides in secretory granules of most (neuro)endocrine cells and neurons, and it is also a plasma marker of neuroendocrine tumors .

HY-P10137

Satoreotide JR11	Somatostatin Receptor	Cancer
Satoreotide (JR11) is a SSTR2 antagonist. Satoreotide is usually conjugated with radiolabeled chelators used in neuroendocrine tumor imaing .

HY-103285

GRP (porcine) Porcine gastrin-releasing peptide 27	Peptides	Cancer
GRP (porcine) (Porcine gastrin-releasing peptide 27) is the putative mammalian analog of Bombesin (HY-P0195). GRP (porcine) activates the release of a number of gastroenteropancreatic (GEP) peptides into the peripheral circulation. GRP (porcine) stimulates gastrin release and exocrine pancreatic secretion. GRP (porcine) is a useful marker of neuroendocrine differentiation in many tumors .

HY-P2434

AP102	Somatostatin Receptor	Neurological Disease Metabolic Disease Cancer
AP102 is a dual SSTR2/SSTR5-specific somatostatin analog (SSA). AP102 is a disulfide-bridged octapeptide SSA containing synthetic iodinated amino acids. AP102 binds with subnanomolar affinity to SSTR2 and SSTR5 (IC₅₀: 0.63 and 0.65 nM, respectively). AP102 does not bind to SSTR1 or SSTR3. AP102 can be used for acromegaly and neuroendocrine tumors research .

Cat. No.	Product Name	Target	Research Area

HY-P9978

Toripalimab	PD-1/PD-L1	Cancer
Toripalimab is the first domestic anti-tumor PD-1 antibody in China. Toripalimab is a selective, recombinant, humanized monoclonal antibody against PD-1. Toripalimab is able to bind to PD-1 and block the interaction with its ligands. Toripalimab has exhibited primary anti-tumor effects in tumors such as melanoma, lung cancer, digestive tract tumors, hepatobiliary and pancreatic tumors, neuroendocrine neoplasms, nasopharyngeal carcinoma and urothelial carcinoma .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W008253

5-Hydroxyindole-3-acetic acid	Structural Classification Monophenols Immune System Disorder Ketones, Aldehydes, Acids Disease markers Phenols Endocrine diseases Nervous System Disorder Endogenous metabolite Cancer	Endogenous Metabolite
5-Hydroxyindole-3-acetic acid is the main metabolite of serotonin or metanephrines, which can be used as a biomarker of neuroendocrine tumors.

HY-W008253R

5-Hydroxyindole-3-acetic acid (Standard)	Structural Classification Monophenols Immune System Disorder Ketones, Aldehydes, Acids Disease markers Phenols Endocrine diseases Nervous System Disorder Endogenous metabolite Cancer	Endogenous Metabolite
5-Hydroxyindole-3-acetic acid (Standard) is the analytical standard of 5-Hydroxyindole-3-acetic acid. This product is intended for research and analytical applications. 5-Hydroxyindole-3-acetic acid is the main metabolite of serotonin or metanephrines, which can be used as a biomarker of neuroendocrine tumors.

Cat. No.	Product Name	Chemical Structure

HY-W008253S1

5-Hydroxyindole-3-acetic acid-d6
5-Hydroxyindole-3-acetic acid-d₆ is the deuterium labeled 5-Hydroxyindole-3-acetic acid. 5-Hydroxyindole-3-acetic acid is the main metabolite of serotonin or metanephrines, which can be used as a biomarker of neuroendocrine tumors.

HY-W008253S

5-Hydroxyindole-3-acetic acid-d2
5-Hydroxyindole-3-acetic acid-d₂ is the deuterium labeled 5-Hydroxyindole-3-acetic acid. 5-Hydroxyindole-3-acetic acid is the main metabolite of serotonin or metanephrines, which can be used as a biomarker of neuroendocrine tumors.

HY-W008253S2

5-Hydroxyindole-3-acetic acid-d5
5-Hydroxyindole-3-acetic acid-d₅is the deuterium labeled5-Hydroxyindole-3-acetic acid(HY-W008253) . 5-Hydroxyindole-3-acetic acid is the main metabolite of serotonin or metanephrines, which can be used as a biomarker of neuroendocrine tumors .

HY-W008253S3

5-Hydroxyindole-3-acetic acid-13C6
5-Hydroxyindole-3-acetic acid- ¹³C₆ is the ¹³C-labeled 5-Hydroxyindole-3-acetic acid. 5-Hydroxyindole-3-acetic acid is the main metabolite of serotonin or metanephrines, which can be used as a biomarker of neuroendocrine tumors.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Name
Email *

	Sorry, but the email address you supplied was invalid.

neuroendocrine tumors

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products